News

ALT fluctuations remained stable for patients with NAFLD throughout disease progression.

Benzodiazepines, eszopiclone, zolpidem, and zopiclone had higher efficacies than melatonin, ramelteon, and zaleplon for insomnia disorder.

Dr. Patrick Flume encourages clinicians to think a little differently when presented with a patient who has a chronic cough without an identifiable cause.

The efficacy of treating insomnia sustained throughout the 24-week postintervention follow-up period for the electroacupuncture treatment group.

Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.

Dipeptidyl peptidase-4 inhibitors have been linked to cases of bullous pemphigoid across Japan, prompting investigators to suggest trying DPP-4i discontinuation followed by supportive care.

Pediatric neurologist and sleep expert Dr. Amy Licis shares available methods to consider when treating a pediatric patient with sleep issues or sleep disorders accompanied by autism or ADHD.

The novel topical skincare treatment Total Eye was effective in treating periorbital wrinkles, dryness, laxity, and dark circles in patients 35-65 years old.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

The NDA was granted Priority Review designation with a PDUFA target action date of November 26, 2022.

With this decision, ruxolitinib cream has become the first treatment approved by the FDA for the repigmentation of skin in vitiligo.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Cohen speaks on combining sun protective measures, such as sunscreen, protective clothing, and antioxidant supplements.

Dr. Lal speaks to how different cultures and different geographical locations can influence UV protection methods, and how sunless tanners can be used to avoid overexposure to UV light outdoors or in tanning beds.

Dr. Craiglow speaks on the public perception of UV safety, how people can best avoid sunburn, and her own personal experience with melanoma and non-melanoma skin cancers.

The authors unanimously agreed that doctors should explain the potential benefits and negatives of the treatment and all centers should have a phototherapy protocol in place to address episodes of symptomatic erythema and other adverse events.

Dr. Harold Edington gives an overview of Australia's public health campaign regarding UV safety, as well as the lessons Americans can take away from these measures.

Investigators uncovered that the primary driving motivator for indoor tanning had to do with aesthetic concerns, followed by the perception of psychological and physical benefits.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Data suggest continued prescribing, not initial prescribing, is linked to opioid addiction risk among exposed family members.

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.

Analysis of patient-reported outcomes last flu season show an approximate 10% increased risk of mild vaccination reactions when receiving both a COVID-19 booster and flu shot instead of a lone booster dose.

More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

The recommendations are for how stakeholders and policy makers should support improvements in managing atopic dermatitis to achieve better disease control and ultimately reducing the costs and burden on individuals, society, and the economy.